<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079803</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-02</org_study_id>
    <secondary_id>R44AG060878</secondary_id>
    <nct_id>NCT04079803</nct_id>
  </id_info>
  <brief_title>PTI-125 for Mild-to-moderate Alzheimer's Disease Patients</brief_title>
  <official_title>A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassava Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of&#xD;
      PTI-125 in mild-to-moderate Alzheimer's disease patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of&#xD;
      PTI-125 in mild-to-moderate Alzheimer's disease patients. A total of sixty (60) patients will&#xD;
      be enrolled in the study. Patients will receive Placebo, 50 mg or 100 mg b.i.d. of PTI-125.&#xD;
      The objective of this study are to investigate the safety, and biomarkers of PTI-125&#xD;
      following 28-day repeat oral administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately sixty (60) patients will be enrolled into the study and randomized to one of three cohorts. Cohorts will receive placebo or PTI-125 at 50 or 100 mg b.i.d. (n=20 per group)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The sponsor, participant, care provider, investigator including sub-investigators and outcomes assessors will be blinded to throughout the study which includes using an Integrated Web Response System (IWRS) and electronic data capture (EDC) to ensure blinding during the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in CSF Abeta42</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid levels of Amyloid beta42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF Total Tau.</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid total tau.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF P-tau181</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid P-tau181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF Neurogranin</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurogranin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF Neurofilament Light Chain</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurofilament light chain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF YKL-40</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening) in cerebrospinal fluid YKL-40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Paired Associates Learning Test</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Cognitive test assessing episodic memory. Boxes are displayed on the screen and are &quot;opened&quot; in a randomized order. One or more of them contains a pattern. The patterns are then displayed in the middle of the screen, one at a time and the participant must select the box in which the pattern was originally located. If the participant makes an error, the boxes are opened in sequence again to remind the participant of the locations of the patterns. The number of boxes increases progressively to a total of 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatial Working Memory Test</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Cognitive assessment of spatial working memory: A number of colored squares (boxes) are shown on the screen. By selecting the boxes and using a process of elimination, the subject should find one yellow 'token' in each of a number of boxes and use them to fill up an empty column on the right-hand side of the screen. The number of boxes is gradually increased to a total of 8 for the subjects to search. The colors and positions of the boxes are changed from trial to trial to discourage stereotyped search strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF IL-6, sTREM2, HMGB1, Albumin, IgG</measure>
    <time_frame>Screening to Day 28</time_frame>
    <description>Change from Baseline (screening sample) to Day 28 in secondary CSF biomarkers of neuroinflammation and blood-brain barrier integrity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Target Engagement Assays: Change From Baseline in Filamin A (FLNA) Linkages to alpha7 Nicotinic Acetylcholine Receptor (alpha7nAChR) and Toll-like Receptor 4 (TLR4) in Subject Lymphocytes</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>FLNA linkages to these two receptors were assessed by densitometric quantitation of immunoblot bands of each receptor (detected by a specific antibody) in anti-FLNA precipitates. The measure is noted as a ratio to total FLNA.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma P-tau181</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Percent change in plasma P-tau181</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in SavaDx, a Novel Plasma Biomarker</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>SavaDx is a novel plasma biomarker</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects administered placebo oral tablets twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam (PTI-125) 100 mg tablets Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam (PTI-125) 50 mg tablets Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Oral placebo tablet</description>
    <arm_group_label>Placebo Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simufilam 100 mg tablet</intervention_name>
    <description>Simufilam 100 mg oral tablet</description>
    <arm_group_label>Simufilam (PTI-125) 50 mg tablets Cohort</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simufilam 50 mg oral tablet</intervention_name>
    <description>Simufilam 50 mg oral tablet</description>
    <arm_group_label>Simufilam (PTI-125) 100 mg tablets Cohort</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages &gt;= 50 and &lt;= 85 years&#xD;
&#xD;
          -  Informed consent form (ICF) signed by the subject or legally acceptable&#xD;
             representative.&#xD;
&#xD;
          -  Clinical diagnosis of dementia due to possible or probable Alzheimer's disease&#xD;
&#xD;
          -  Mini-Mental State Examination score &gt;= 16 and &lt;= 26 at screening&#xD;
&#xD;
          -  If female, postmenopausal for at least 1 year&#xD;
&#xD;
          -  Patient living at home, senior residential setting, or an institutional setting&#xD;
             without the need for continuous (i.e. 24-h) nursing care&#xD;
&#xD;
          -  General health status acceptable for participation in the study&#xD;
&#xD;
          -  Fluency (oral and written) in English or Spanish&#xD;
&#xD;
          -  If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose&#xD;
             for at least 3 months. If receiving donepezil, any dose lower than 23 mg once daily.&#xD;
&#xD;
          -  The patient is a non-smoker for at least 3 years.&#xD;
&#xD;
          -  The patient or legal representative must agree to comply with the drawing of blood&#xD;
             samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.&#xD;
&#xD;
          -  The patient has a ratio of total tau/Aβ42 in cerebrospinal fluid &gt;= 0.28.&#xD;
&#xD;
          -  Patient has a caregiver or legal representative responsible for administering the drug&#xD;
             and recording the time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to an experimental drug, experimental biologic or experimental medical device&#xD;
             within the longer of 5 half-lives or 3 months before screening&#xD;
&#xD;
          -  Enrollment in the previous PTI-125 trial&#xD;
&#xD;
          -  A medical condition that would interfere with a lumbar puncture&#xD;
&#xD;
          -  Residence in a skilled nursing facility and requiring 24 h care.&#xD;
&#xD;
          -  Clinically significant laboratory test results&#xD;
&#xD;
          -  Clinically significant untreated hypothyroidism&#xD;
&#xD;
          -  Insufficiently controlled diabetes mellitus&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt; ULN)&#xD;
&#xD;
          -  Malignant tumor within 3 years before screening (except squamous and basal cell&#xD;
             carcinoma or cervical carcinoma in situ or localized prostate cancer or localized&#xD;
             stage 1 bladder cancer)&#xD;
&#xD;
          -  History of ischemic colitis or ischemic enterocolitis&#xD;
&#xD;
          -  Unstable medical condition that is clinically significant in the judgment of the&#xD;
             investigator&#xD;
&#xD;
          -  Alanine transaminase (ALT) or aspartate transaminase (AST) &gt; ULN or total bilirubin &gt;&#xD;
             ULN.&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months before screening&#xD;
&#xD;
          -  History of more than 1 myocardial infarction within 5 years before screening&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia (including atrial fibrillation),&#xD;
             cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are&#xD;
             acceptable)&#xD;
&#xD;
          -  Symptomatic hypotension, or uncontrolled hypertension&#xD;
&#xD;
          -  Clinically significant abnormality on screening electrocardiogram (ECG), including but&#xD;
             not necessarily limited to a confirmed corrected QT interval value &gt;= 450 msec for&#xD;
             males or &gt;= 470 msec for females.&#xD;
&#xD;
          -  Stroke within 18 months before screening, or history of a stroke concomitant with&#xD;
             onset of dementia&#xD;
&#xD;
          -  History of brain tumor or other clinically significant space-occupying lesion on CT or&#xD;
             MRI&#xD;
&#xD;
          -  Head trauma with clinically significant loss of consciousness within 12 months before&#xD;
             screening or concurrent with the onset of dementia&#xD;
&#xD;
          -  Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or&#xD;
             resuscitation&#xD;
&#xD;
          -  Specific degenerative Central Nervous System disease diagnosis other than Alzheimer's&#xD;
             disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome,&#xD;
             Frontotemporal Dementia, Parkinson's disease)&#xD;
&#xD;
          -  Wernicke's encephalopathy&#xD;
&#xD;
          -  Active acute or chronic Central Nervous System infection&#xD;
&#xD;
          -  Donepezil 23 mg quaque die currently or within 3 months prior to randomization&#xD;
&#xD;
          -  Discontinued AChEI &lt; 30 days prior to randomization&#xD;
&#xD;
          -  Antipsychotics; low doses are allowed only if the subject has received a stable dose&#xD;
             for at least 3 months before randomization&#xD;
&#xD;
          -  Tricyclic antidepressants and monoamine oxidase inhibitors&#xD;
&#xD;
          -  Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses&#xD;
             for benign tremor); low doses of benzodiazepines and zolpidem are allowed&#xD;
&#xD;
          -  Immunosuppressants, including systemic corticosteroids, if taken in clinically&#xD;
             immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)&#xD;
&#xD;
          -  Antiepileptic medications if taken for control of seizures&#xD;
&#xD;
          -  Chronic intake of opioid-containing analgesics&#xD;
&#xD;
          -  Sedating H1 antihistamines&#xD;
&#xD;
          -  Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or&#xD;
             similar therapeutic agent within 30 days before screening&#xD;
&#xD;
          -  Clinically significant illness within 30 days of enrollment&#xD;
&#xD;
          -  History of significant neurological, hepatic, renal, endocrine, cardiovascular,&#xD;
             gastrointestinal, pulmonary, or metabolic disease&#xD;
&#xD;
          -  Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus HCV&#xD;
             antibody test at screening&#xD;
&#xD;
          -  Positive HIV test at screening&#xD;
&#xD;
          -  Positive urine drug test at screening&#xD;
&#xD;
          -  Loss of a significant volume of blood (&gt; 450 mL) within 4 weeks prior to the study&#xD;
&#xD;
          -  Suicidality on C-SSRS at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Burns, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cassava Sciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus U</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC, Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://nnjournal.net/article/view/2313</url>
    <description>Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease</description>
  </link>
  <link>
    <url>http://www.cassavasciences.com/science/publications</url>
    <description>PTI-125 and Alzheimer's Publications</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <results_first_submitted>April 12, 2021</results_first_submitted>
  <results_first_submitted_qc>May 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2021</results_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04079803/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04079803/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04079803/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Cohort</title>
          <description>Subjects administered placebo oral tablets twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
          <description>Subjects administered simufilam 100 mg oral tablets twice daily (BID)</description>
        </group>
        <group group_id="P3">
          <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
          <description>Subjects administered simufilam 50 mg oral tablets twice daily (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Cohort</title>
          <description>Subjects administered matching placebo tablets twice daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
          <description>Subjects administered 100 mg simufilam tablets twice daily for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
          <description>Subjects administered 50 mg simufilam tablets twice daily for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="6.68"/>
                    <measurement group_id="B2" value="69.3" spread="5.47"/>
                    <measurement group_id="B3" value="67.1" spread="8.76"/>
                    <measurement group_id="B4" value="69.2" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF total tau/Aβ42 ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.20" spread="0.55"/>
                    <measurement group_id="B2" value="1.08" spread="0.50"/>
                    <measurement group_id="B3" value="1.17" spread="0.58"/>
                    <measurement group_id="B4" value="1.15" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-Mental State Exam (MMSE)</title>
          <description>The MMSE is a is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills. It is often used to stage Alzheimer's disease. The scale ranges from 0 to 30. No errors = 30.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="2.78"/>
                    <measurement group_id="B2" value="23.0" spread="2.66"/>
                    <measurement group_id="B3" value="22.7" spread="2.67"/>
                    <measurement group_id="B4" value="22.9" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking cholinesterase inhibitor or memantine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heterozygous APOE4</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homozygous APOE4</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paired Associates Learning total errors</title>
          <description>Boxes are displayed on the screen and are &quot;opened&quot; in a randomized order. One or more of them contains a pattern. The patterns are then displayed in the middle of the screen, one at a time and the participant must select the box in which the pattern was originally located. If the participant makes an error, the boxes are opened in sequence again to remind the participant of the locations of the patterns. The number of boxes increases progressively to a total of 8.</description>
          <population>The least impaired patients (11 or fewer errors, representing a ceiling effect) and patients with 54 or more errors (very poor performance suggesting not understanding the task) were removed from the analysis. Also removed were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes.</population>
          <units>errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="19.65"/>
                    <measurement group_id="B2" value="31.0" spread="20.74"/>
                    <measurement group_id="B3" value="36.1" spread="18.76"/>
                    <measurement group_id="B4" value="34.2" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spatial Working Memory total errors</title>
          <description>A number of colored squares (boxes) are shown on the screen. By selecting the boxes and using a process of elimination, the subject should find one yellow 'token' in each of a number of boxes and use them to fill up an empty column on the right-hand side of the screen. The number of boxes is gradually increased to a total of 8 for the subjects to search. The colors and positions of the boxes are changed from trial to trial to discourage stereotyped search strategies.</description>
          <population>Removed from analysis were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes</population>
          <units>errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="7.49"/>
                    <measurement group_id="B2" value="22.1" spread="5.88"/>
                    <measurement group_id="B3" value="22.3" spread="6.64"/>
                    <measurement group_id="B4" value="21.1" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF Aβ42</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125" spread="152"/>
                    <measurement group_id="B2" value="117" spread="51.4"/>
                    <measurement group_id="B3" value="108" spread="54.8"/>
                    <measurement group_id="B4" value="111" spread="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF total tau</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104" spread="32"/>
                    <measurement group_id="B2" value="106" spread="27.9"/>
                    <measurement group_id="B3" value="101" spread="17.6"/>
                    <measurement group_id="B4" value="103.7" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF P-tau181</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="0.73"/>
                    <measurement group_id="B2" value="29.7" spread="1.5"/>
                    <measurement group_id="B3" value="29.0" spread="1.0"/>
                    <measurement group_id="B4" value="29.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF neurogranin</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1200" spread="365"/>
                    <measurement group_id="B2" value="1551" spread="751"/>
                    <measurement group_id="B3" value="1352" spread="614"/>
                    <measurement group_id="B4" value="1368" spread="577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF Neurofilament Light Chain</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161" spread="42.8"/>
                    <measurement group_id="B2" value="219" spread="95.3"/>
                    <measurement group_id="B3" value="181" spread="64.4"/>
                    <measurement group_id="B4" value="187" spread="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF YKL-40</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206" spread="29.5"/>
                    <measurement group_id="B2" value="203" spread="22.7"/>
                    <measurement group_id="B3" value="194" spread="26.0"/>
                    <measurement group_id="B4" value="201" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF IL-6</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="1.2"/>
                    <measurement group_id="B2" value="33.6" spread="1.8"/>
                    <measurement group_id="B3" value="33.6" spread="1.7"/>
                    <measurement group_id="B4" value="33.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF sTREM2</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="878" spread="435"/>
                    <measurement group_id="B2" value="861" spread="421"/>
                    <measurement group_id="B3" value="882" spread="476"/>
                    <measurement group_id="B4" value="874" spread="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF HMGB1</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="424" spread="48.0"/>
                    <measurement group_id="B2" value="446" spread="67.3"/>
                    <measurement group_id="B3" value="454" spread="70.6"/>
                    <measurement group_id="B4" value="441" spread="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF/plasma albumin ratio</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.24" spread="0.03"/>
                    <measurement group_id="B2" value="0.25" spread="0.08"/>
                    <measurement group_id="B3" value="0.25" spread="0.05"/>
                    <measurement group_id="B4" value="0.25" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF/plasma IgG ratio</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.200" spread="0.07"/>
                    <measurement group_id="B2" value="0.217" spread="0.11"/>
                    <measurement group_id="B3" value="0.227" spread="0.07"/>
                    <measurement group_id="B4" value="0.215" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphocyte filamin A - α7nAChR, Ratio to total filamin A</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.59" spread="0.10"/>
                    <measurement group_id="B2" value="0.69" spread="0.11"/>
                    <measurement group_id="B3" value="0.66" spread="0.12"/>
                    <measurement group_id="B4" value="0.65" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphocyte filamin A - TLR4, Ratio to total filamin A</title>
          <population>One subject is missing a CSF sample. Three others had no detectable simufilam in plasma and were excluded from analyses.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.55" spread="0.10"/>
                    <measurement group_id="B2" value="0.60" spread="0.07"/>
                    <measurement group_id="B3" value="0.58" spread="0.11"/>
                    <measurement group_id="B4" value="0.58" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF Abeta42</title>
        <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid levels of Amyloid beta42</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo tablets BID for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>simufilam 100 mg tablets BID for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>simufilam 50 mg tablets BID for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Abeta42</title>
          <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid levels of Amyloid beta42</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="30.9"/>
                    <measurement group_id="O2" value="12.5" spread="11.9"/>
                    <measurement group_id="O3" value="16.2" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P=0.0088 and CFB was 13.4. In percent change from baseline with these two subjects removed, P=0.004.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.0006 and CFB was 16.9. In percent change from baseline with this subject removed, P=0.0004.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF Total Tau.</title>
        <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid total tau.</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125) 100 mg Tablets Cohort</title>
            <description>Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125) 50 mg Tablets Cohort</title>
            <description>SImufilam (PTI-125) 50 mg oral tablets administered twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Total Tau.</title>
          <description>Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid total tau.</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="14.8"/>
                    <measurement group_id="O2" value="-18.7" spread="10.4"/>
                    <measurement group_id="O3" value="-14.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P&lt;0.0001 and CFB was -19.8.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.001 and CFB was -14.9.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF P-tau181</title>
        <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid P-tau181</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo tablets BID for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>simufilam 100 mg tablets BID for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>simufilam 50 mg tablets BID for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF P-tau181</title>
          <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid P-tau181</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="1.8"/>
                    <measurement group_id="O2" value="-3.1" spread="1.7"/>
                    <measurement group_id="O3" value="-2.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P=0.003 and CFB was -3.2.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.003 and CFB was -2.5.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF Neurogranin</title>
        <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurogranin</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo tablets BID for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>simufilam 100 mg tablets BID for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>simufilam 50 mg tablets BID for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Neurogranin</title>
          <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurogranin</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.5" spread="434"/>
                    <measurement group_id="O2" value="-648" spread="491"/>
                    <measurement group_id="O3" value="-527" spread="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P=0.0002 and CFB was -681.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.0005 and CFB was -527.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF Neurofilament Light Chain</title>
        <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurofilament light chain</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo tablets BID for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>simufilam 100 mg tablets BID for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>simufilam 50 mg tablets BID for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Neurofilament Light Chain</title>
          <description>Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurofilament light chain</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="45"/>
                    <measurement group_id="O2" value="-76.3" spread="50.6"/>
                    <measurement group_id="O3" value="-49.7" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P=0.0002 and CFB was -78.5.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0058</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.0008 and CFB was -51.0.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF YKL-40</title>
        <description>Change from Baseline (screening) in cerebrospinal fluid YKL-40</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo tablets BID for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>simufilam 100 mg tablets BID for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>simufilam 50 mg tablets BID for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF YKL-40</title>
          <description>Change from Baseline (screening) in cerebrospinal fluid YKL-40</description>
          <population>As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample. This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="24.2"/>
                    <measurement group_id="O2" value="-22.3" spread="11.7"/>
                    <measurement group_id="O3" value="-20.4" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes two 100 mg subjects who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing two subjects with no detectable simufilam in plasma, P=0.0001 and CFB was -23.7.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This primary analysis includes one 50 mg subject who showed no detectable simufilam in plasma at return visits (their exclusion was not prespecified in the Statistical Analysis Plan).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P value adjusted for multiplicity of 6 co-primary endpoints (p&lt;0.008 required for significance).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
            <other_analysis_desc>In a secondary analysis removing one subject with no detectable simufilam in plasma, P=0.0002 and CFB was -20.9.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paired Associates Learning Test</title>
        <description>Cognitive test assessing episodic memory. Boxes are displayed on the screen and are &quot;opened&quot; in a randomized order. One or more of them contains a pattern. The patterns are then displayed in the middle of the screen, one at a time and the participant must select the box in which the pattern was originally located. If the participant makes an error, the boxes are opened in sequence again to remind the participant of the locations of the patterns. The number of boxes increases progressively to a total of 8.</description>
        <time_frame>Day 1 to Day 28</time_frame>
        <population>The least impaired patients (11 or fewer errors, representing a ceiling effect) and patients with 54 or more errors (very poor performance suggesting not understanding the task) were removed from the analysis. Also removed were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo oral tablets administered twice daily (BID) for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>Simufilam 100 mg oral tablets administered twice daily (BID) for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>Simufilam 50 mg oral tablets administered twice daily (BID) for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Paired Associates Learning Test</title>
          <description>Cognitive test assessing episodic memory. Boxes are displayed on the screen and are &quot;opened&quot; in a randomized order. One or more of them contains a pattern. The patterns are then displayed in the middle of the screen, one at a time and the participant must select the box in which the pattern was originally located. If the participant makes an error, the boxes are opened in sequence again to remind the participant of the locations of the patterns. The number of boxes increases progressively to a total of 8.</description>
          <population>The least impaired patients (11 or fewer errors, representing a ceiling effect) and patients with 54 or more errors (very poor performance suggesting not understanding the task) were removed from the analysis. Also removed were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes.</population>
          <units>Change from Day 1 in total errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.5"/>
                    <measurement group_id="O2" value="-4.5" spread="17.7"/>
                    <measurement group_id="O3" value="-5.7" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was not powered for statistical significance on cognitive measures.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect size</param_type>
            <param_value>0.23</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Reported effect size vs. placebo was calculated with Hedge's g (for groups of 20 or fewer) but was identical when calculated by Cohen's d.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This study was not powered for statistical significance on cognitive measures.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect size</param_type>
            <param_value>0.37</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Reported effect size vs. placebo was calculated with Hedge's g (for groups of 20 or fewer) but was identical when calculated by Cohen's d.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spatial Working Memory Test</title>
        <description>Cognitive assessment of spatial working memory: A number of colored squares (boxes) are shown on the screen. By selecting the boxes and using a process of elimination, the subject should find one yellow 'token' in each of a number of boxes and use them to fill up an empty column on the right-hand side of the screen. The number of boxes is gradually increased to a total of 8 for the subjects to search. The colors and positions of the boxes are changed from trial to trial to discourage stereotyped search strategies.</description>
        <time_frame>Day 1 to Day 28</time_frame>
        <population>Removed from analysis were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>Simufilam, 100 mg oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>Simufilam, 50 mg oral tablets administered twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Spatial Working Memory Test</title>
          <description>Cognitive assessment of spatial working memory: A number of colored squares (boxes) are shown on the screen. By selecting the boxes and using a process of elimination, the subject should find one yellow 'token' in each of a number of boxes and use them to fill up an empty column on the right-hand side of the screen. The number of boxes is gradually increased to a total of 8 for the subjects to search. The colors and positions of the boxes are changed from trial to trial to discourage stereotyped search strategies.</description>
          <population>Removed from analysis were the 3 patients with no detectable drug in plasma, 2 patients with ≥25% non-compliance by pill counts, one patient with no baseline test and one who did not understand instructions per rater notes.</population>
          <units>Change from Day 1 in total errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="7.54"/>
                    <measurement group_id="O2" value="-2.31" spread="7.45"/>
                    <measurement group_id="O3" value="-3.35" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was not powered for statistical significance on cognitive measures.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect size</param_type>
            <param_value>0.46</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Reported effect size vs. placebo was calculated with Hedge's g (for groups of 20 or fewer) but was almost identical (0.45) when calculated by Cohen's d.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This study was not powered for statistical significance on cognitive measures.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect size</param_type>
            <param_value>0.25</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Reported effect size vs. placebo was calculated with Hedge's g (for groups of 20 or fewer) but was identical when calculated by Cohen's d.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF IL-6, sTREM2, HMGB1, Albumin, IgG</title>
        <description>Change from Baseline (screening sample) to Day 28 in secondary CSF biomarkers of neuroinflammation and blood-brain barrier integrity</description>
        <time_frame>Screening to Day 28</time_frame>
        <population>Three subjects who had no detectable simufilam in plasma at return visits were removed from analyses (two in the 100 mg arm and one in the 50 mg arm). As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>Simufilam, 100 mg oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>Simufilam, 50 mg oral tablets administered twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>CSF IL-6, sTREM2, HMGB1, Albumin, IgG</title>
          <description>Change from Baseline (screening sample) to Day 28 in secondary CSF biomarkers of neuroinflammation and blood-brain barrier integrity</description>
          <population>Three subjects who had no detectable simufilam in plasma at return visits were removed from analyses (two in the 100 mg arm and one in the 50 mg arm). As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. One additional subject in the 50 mg arm was missing a Day 28 CSF sample.</population>
          <units>pg/mL; optical density for albumin &amp; IgG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSF IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.0"/>
                    <measurement group_id="O2" value="-3.7" spread="1.8"/>
                    <measurement group_id="O3" value="-3.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF sTREM2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.3" spread="510"/>
                    <measurement group_id="O2" value="-426" spread="274"/>
                    <measurement group_id="O3" value="-424" spread="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF HMGB1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="172.3"/>
                    <measurement group_id="O2" value="-143" spread="51.3"/>
                    <measurement group_id="O3" value="-152" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-240" spread="1620"/>
                    <measurement group_id="O2" value="-2292" spread="1760"/>
                    <measurement group_id="O3" value="-1245" spread="1735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-574.8" spread="2518"/>
                    <measurement group_id="O2" value="-2350" spread="2517"/>
                    <measurement group_id="O3" value="-2444" spread="2097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is for IL-6.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is for IL-6.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is for sTREM2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is for sTREM2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is for HMGB1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is for HMGB1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is for albumin.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is for albumin.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is for Immunoglobulin G.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is for Immunoglobulin G.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Secondary CSF biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>General Linear Model for the analysis of covariance (ANCOVA) with a two-sided 95% confidence interval and baseline measurement as the covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Target Engagement Assays: Change From Baseline in Filamin A (FLNA) Linkages to alpha7 Nicotinic Acetylcholine Receptor (alpha7nAChR) and Toll-like Receptor 4 (TLR4) in Subject Lymphocytes</title>
        <description>FLNA linkages to these two receptors were assessed by densitometric quantitation of immunoblot bands of each receptor (detected by a specific antibody) in anti-FLNA precipitates. The measure is noted as a ratio to total FLNA.</description>
        <time_frame>Day 1 to Day 28</time_frame>
        <population>Three subjects who had no detectable simufilam in plasma at any return visit were removed from analyses (two in the 100 mg arm and one in the 50 mg arm). As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. Two additional subjects in the 50 mg arm were missing Day 1 blood samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Placebo oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>Simufilam, 100 mg oral tablets administered twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>Simufilam, 50 mg oral tablets administered twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Engagement Assays: Change From Baseline in Filamin A (FLNA) Linkages to alpha7 Nicotinic Acetylcholine Receptor (alpha7nAChR) and Toll-like Receptor 4 (TLR4) in Subject Lymphocytes</title>
          <description>FLNA linkages to these two receptors were assessed by densitometric quantitation of immunoblot bands of each receptor (detected by a specific antibody) in anti-FLNA precipitates. The measure is noted as a ratio to total FLNA.</description>
          <population>Three subjects who had no detectable simufilam in plasma at any return visit were removed from analyses (two in the 100 mg arm and one in the 50 mg arm). As noted in the Participant Flow, one subject in the 50 mg arm did not complete the study. Two additional subjects in the 50 mg arm were missing Day 1 blood samples.</population>
          <units>ratio to total FLNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FLNA - alpha7nAChR linkage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.19"/>
                    <measurement group_id="O2" value="-0.24" spread="0.16"/>
                    <measurement group_id="O3" value="-0.23" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLNA - TLR4 linkage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.18"/>
                    <measurement group_id="O2" value="-0.19" spread="0.14"/>
                    <measurement group_id="O3" value="-0.19" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in FLNA linkage to alpha7nAChR in subject lymphocytes. FLNA linkage to alpha7nAChR was expressed as the ratio of densitometric units of immunoblot bands of alpha7nAChR (probed with a specific antibody) to densitometric units of total FLNA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>As secondary endpoints, lymphocyte biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA was used instead of ANCOVA due to the range in baseline values; it was deemed more appropriate to compare to each subject's own baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in FLNA linkage to alpha7nAChR in subject lymphocytes. FLNA linkage to alpha7nAChR was expressed as ratios of densitometric units of immunoblot bands of alpha7nAChR (probed with a specific antibody) to densitometric units of total FLNA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>As secondary endpoints, lymphocyte biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA was used instead of ANCOVA due to the range in baseline values; it was deemed more appropriate to compare to each subject's own baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in FLNA linkage to TLR4 in subject lymphocytes. FLNA linkage to TLR4 was expressed as the ratio of densitometric units of immunoblot bands of TLR4 (probed with a specific antibody) to densitometric units of total FLNA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>As secondary endpoints, lymphocyte biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA was used instead of ANCOVA due to the range in baseline values; it was deemed more appropriate to compare to each subject's own baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in FLNA linkage to TLR4 in subject lymphocytes. FLNA linkage to TLR4 was expressed as the ratio of densitometric units of immunoblot bands of TLR4 (probed with a specific antibody) to densitometric units of total FLNA.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>As secondary endpoints, lymphocyte biomarkers were not adjusted for multiplicity.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA was used instead of ANCOVA due to the range in baseline values; it was deemed more appropriate to compare to each subject's own baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma P-tau181</title>
        <description>Percent change in plasma P-tau181</description>
        <time_frame>Day 1 to Day 28</time_frame>
        <population>For plasma p-tau181 only: 4 subjects (1 in placebo, 2 in 50 mg and 1 in 100 mg arms) were removed because Coefficients of Variation (CVs) between duplicate measurements for either Day 1 or Day 28 samples were &gt;15% on repeat assay (both Day 1 &amp; Day 28 for a subject were repeated if CVs of either Day 1 or Day 28 were &gt;11%). Two outliers were removed (1 in placebo [1.2 to 4.8 pg/ml] and 1 in 100 mg [2.1 to 5.1 pg/ml] arms) for increases &gt;150% &amp; &gt; 2.5 pg/mL. Missing Day 1 blood samples: 2 in 50 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Subjects administered placebo oral tablets twice daily (BID)&#xD;
Placebo oral tablet: Oral placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125) 100 mg Tablets Cohort</title>
            <description>Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)&#xD;
Simufilam 50 mg oral tablet: Simufilam 50 mg oral tablet</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125) 50 mg Tablets Cohort</title>
            <description>Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)&#xD;
Simufilam 100 mg tablet: Simufilam 100 mg oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma P-tau181</title>
          <description>Percent change in plasma P-tau181</description>
          <population>For plasma p-tau181 only: 4 subjects (1 in placebo, 2 in 50 mg and 1 in 100 mg arms) were removed because Coefficients of Variation (CVs) between duplicate measurements for either Day 1 or Day 28 samples were &gt;15% on repeat assay (both Day 1 &amp; Day 28 for a subject were repeated if CVs of either Day 1 or Day 28 were &gt;11%). Two outliers were removed (1 in placebo [1.2 to 4.8 pg/ml] and 1 in 100 mg [2.1 to 5.1 pg/ml] arms) for increases &gt;150% &amp; &gt; 2.5 pg/mL. Missing Day 1 blood samples: 2 in 50 mg.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="49"/>
                    <measurement group_id="O2" value="-16.5" spread="29"/>
                    <measurement group_id="O3" value="-15.1" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA followed by Dunnett's multiple comparisons test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA followed by Dunnett's multiple comparisons test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
            <method_desc>This p value is for the main effect of treatment of the ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in SavaDx, a Novel Plasma Biomarker</title>
        <description>SavaDx is a novel plasma biomarker</description>
        <time_frame>Day 1 to Day 28</time_frame>
        <population>One subject in the 50 mg arm and two subjects in the 100 mg arm were omitted because these subjects showed no detectable plasma simufilam at any return visit. Two additional subjects in the 50 mg group were missing baseline plasma samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort</title>
            <description>Subjects administered placebo oral tablets twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
            <description>Subjects administered simufilam 100 mg oral tablets twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
            <description>Subjects administered simufilam 50 mg oral tablets twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in SavaDx, a Novel Plasma Biomarker</title>
          <description>SavaDx is a novel plasma biomarker</description>
          <population>One subject in the 50 mg arm and two subjects in the 100 mg arm were omitted because these subjects showed no detectable plasma simufilam at any return visit. Two additional subjects in the 50 mg group were missing baseline plasma samples.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="62"/>
                    <measurement group_id="O2" value="-47.8" spread="19"/>
                    <measurement group_id="O3" value="-44.1" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Cohort</title>
          <description>Subjects administered placebo tablets twice daily (BID) for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Simufilam (PTI-125), 100 mg Tablets Cohort</title>
          <description>Subjects administered simufilam 100 mg tablets twice daily (BID) for 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Simufilam (PTI-125), 50 mg Tablets Cohort</title>
          <description>Subjects administered simufilam 50 mg tablets twice daily (BID) for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any adverse event</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadav Friedmann, PhD, MD, Chief Medical Officer</name_or_title>
      <organization>Cassava Sciences, Inc.</organization>
      <phone>512-501-1900</phone>
      <email>nfriedmann@cassavasciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

